Flow: FDA-Approved Brain Stimulation

The Depression Treatment Crisis

Depression is the leading cause of disability worldwide. Over 280 million people live with depression globally. Treatment options remain limited despite decades of pharmaceutical development. Antidepressant medications like SSRIs help some patients, but many experience significant side effects. Weight gain, sexual dysfunction, emotional numbing, and sleep disruption drive patients to abandon treatment. About one-third of people with depression don't respond adequately to any medication. Those who do respond often spend years trying multiple drugs at different doses to find one they tolerate. Meanwhile, traditional talk therapy has long waitlists in most countries. Hospital-based brain stimulation treatments exist but require travel, multiple appointments, and general anesthesia. The treatment landscape leaves millions suffering without good options.

A Swedish medical device company spent years researching an alternative approach. Rather than target neurotransmitters through chemicals, they applied a well-researched neuroscience technique to a consumer format. Flow Neuroscience developed a headset that delivers transcranial direct current stimulation, or tDCS, directly to the brain regions that regulate mood. The device recently achieved a historic regulatory milestone.

How Flow Delivers Brain Stimulation at Home

Depression often involves reduced neural activity in the left prefrontal cortex, the brain region controlling emotional expression and cognitive regulation. Flow delivers a mild electrical current through two electrode pads placed on the scalp. This current stimulates neurons in the prefrontal cortex and helps rebalance activity. The approach is non-invasive, meaning no surgery is required. The current is low intensity, similar to what the brain generates naturally. Sessions last 30 minutes and can be completed at home while using an app-based therapy program.

The headset uses what clinicians call transcranial direct current stimulation. tDCS has been studied for over 25 years in research settings and clinical trials. Hundreds of peer-reviewed studies document its effects on brain activity and depression symptoms. What makes Flow's headset novel is combining tDCS with a structured therapy program and enabling home-based treatment supervised remotely by healthcare professionals. Previous tDCS devices required visits to specialized clinics or hospitals. Flow's wireless design with integrated app guidance transforms this technology into an accessible home treatment.

FDA Approval and Clinical Evidence

A rigorous clinical trial validated Flow's approach. The trial enrolled 174 people diagnosed with major depressive disorder. Participants were randomly assigned to use the Flow headset with active stimulation, the headset with sham stimulation (placebo), or neither. All groups received remote therapy guidance. The trial lasted 10 weeks with daily sessions.

Results published in Nature Medicine showed significant benefits. Active tDCS produced two to three times higher remission and response rates compared to sham. Within three weeks, 77 percent of users reported clinical improvement. By week ten, 57 percent were completely free of depression, meeting rigorous clinical remission criteria. The improvement rates exceeded those typically seen with antidepressant medications in similar trials.

Safety monitoring found the treatment well-tolerated. Minor side effects included occasional tingling at electrode sites, but no serious adverse events occurred. This safety profile contrasts sharply with antidepressants, where metabolic side effects and sexual dysfunction affect many users long-term.

Global Market Validation and US Expansion

Flow has been available outside the United States for years. The device received CE marking in Europe, making it the first approved at-home tDCS headset available for home purchase. Since launching, the company reports treating over 55,000 patients across Europe and the United Kingdom. The National Health Service in the United Kingdom approved Flow for use in hospital clinics and community mental health services. Ten separate NHS services have published their own real-world results, all confirming the trial findings.

This real-world evidence from thousands of patients strengthened Flow's FDA submission significantly. When regulatory agencies see that a device works in clinical trials and continues working across diverse patient populations in everyday settings, approval becomes more likely.